(Press-News.org) "The study was designed to show a better 4-hour survival in the group treated with mechanical chest compressions, and this was not achieved," said lead investigator Sten Rubertsson, MD, PhD, professor and specialist consultant at Uppsala University and Uppsala University Hospital.
"But we now have the scientific support to allow us to use mechanical chest compressions and defibrillate during ongoing compressions," he said, adding that this could potentially increase the efficiency and safety of emergency personnel as they deliver care during transportation of patients.
The LINC study included 2,589 patients from six European sites who had suffered an out-of-hospital cardiac arrest and needed resuscitation.
Manual chest compressions were started on all patients as soon as EMS personnel arrived on the scene.
Patients were then randomized to either be kept on manual chest compressions (n=1289) or be switched to mechanical compressions with defibrillation during ongoing chest compressions (n=1300). Mechanical chest compressions were delivered with the LUCAS Chest Compression System (Physio-Control/Jolife AB, Lund Sweden), a piston-driven device with a suction cup designed to deliver compressions according to resuscitation guidelines.
In both groups, ventilation and drugs were given according to guidelines.
The study showed that four hours after the initiation of CPR, survival rates were similar in both the mechanical and manual CPR groups (23.6% versus 23.7%).
Later outcomes were also similar, including the rate of restoration of spontaneous circulation (ROSC), the number of patients who arrived at the emergency room with a palpable pulse, the number of patients who survived until discharge from intensive care, and neurological outcomes at one and six months.
Theoretically, mechanical chest compressions should offer an advantage over manual chest compressions because the latter often have insufficient depth, incorrect rate and frequent interruptions, explained Dr. Rubertsson.
"The efficacy of traditional manual chest compression is heavily dependent on the skills and endurance of rescuers, and is compromised by periods of hands-off time and transportation interruptions," he said. Even at high efficiency it delivers only approximately 30% of normal cardiac output, resulting in decreased blood flow to vital organs."
Mechanical compressions should theoretically improve CPR, but to date there is no definitive evidence from large randomised trials to show this.
Two randomized pilot studies of out-of-hospital cardiac arrest patients have compared mechanical chest compressions with mechanical compressions from the LUCAS device (1-2), and neither study found any significant difference between groups; however, the study populations were small.
The results of the current study suggest clinical equipoise, said Dr. Rubertsson - although, he said slight adjustments to the treatment algorithms might result in clinically significant differences in the future.
"With the algorithm we used for mechanical CPR we found that time to first defibrillation was delayed compared to manual CPR and this could explain why we were not able to show improved outcome. Therefore in the future we will recommend defibrillation without delay, before deployment of the device."
Regarding safety, "I would say that we can deem the device is safe, based upon the low number of severe adverse events and adverse events reported in the study, " he said.
"Survivors at 6 months had good neurologic outcome (99% in the mechanical group and 94% in the manual) and in a previously published pilot study of 85 patients we did not find any difference between groups in injuries at autopsy. What remains to be finally analysed is the cohort of 200 patients within LINC that underwent autopsy."
Evidence showing equal efficacy for both manual and mechanical compressions is an added benefit to Emergency Medical Systems (EMS) workers.
"EMS workers can now use a device to provide CPR which means they have an extra pair of hands available for other possible interventions," said Dr. Rubertsson.
"Safety during transportation in the ambulance can also be improved since now the crew can have safety belts and still provide CPR."
He emphasized that the results of the LINC trial are only applicable to the LUCAS device and cannot be generalized to other mechanical chest compressors.
INFORMATION:
References:
1. Axelsson C, Nestin J, Svensson L, Axelsson A.B, Herlitz J. Clinical consequences of the introduction of mechanical chest compression in the EMS system for treatment of out-of-hospital cardiac arrest-a pilot study. Resuscitation 2006;71:47-55.
2. Smekal D, Johansson J, Huzevka T, Rubertsson S. A pilot study of mechanical chest compressions with the LUCAS device in cardiopulmonary resuscitation. Resuscitation 2011;82:702-06.
FUNDING: The LINC study was initiated by Uppsala University and sponsored by Physio-Control/Jolife AB.
DISCLOSURES:
Sten Rubertsson has received consultation fee from Physio-Control/Jolife AB. All the other authors' institutions received funding from Physio-Control/Jolife AB as compensation for the work.
Notes to editor
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2013
The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information is available from the ESC Press Office at press@escardio.org
END
AMSTERDAM, The Netherlands – In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of Delayed Enhancement - MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.
"The DECAAF results show that stage of atrial fibrosis prior to ablation is a new, powerful, independent predictor of outcome," said lead investigator Nasir ...
AMSTERDAM, The Netherlands – In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.
In the landscape of new trials with oral anticoagulants, the Hokusai-VTE findings offer fresh insight into a previously under-represented subgroup of patients with pulmonary embolism (PE), suggesting that treatment for this group might need to be different than ...
AMSTERDAM, The Netherlands -- Aspiration of the blood clot or "thrombus" that causes a heart attack before re-opening a patient's artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone according to the results of the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial.
"We believe that TASTE questions the usefulness of thrombus aspiration as a routine adjunct and the recommendation for its general use in international guidelines should probably be down-graded," said lead author ...
Dr Lin said: "Statins are widely used in the older population to reduce the risk of cardiovascular disease. But recent reports of statin-associated cognitive impairment have led the US Food and Drug Administration (FDA) to list statin-induced cognitive changes, especially for the older population, in its safety communications."
He added: "Previous studies had considered statin therapy to exert a beneficial effect on dementia. But few large-scale studies have focused on the impact of statins on new-onset, non-vascular dementia in the geriatric population."
Accordingly, ...
Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown."
Between June 2008 and February 2009 DYSIS assessed the prevalence and types of persistent lipid abnormalities in patients receiving statins. Eligible patients were at high risk of a cardiovascular event, aged >45 years, and had been on chronic statin treatment for at least three months. A total of 22,063 patients were enrolled from 2,954 sites across 11 European ...
Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown that aggressive cholesterol lowering with statins improves clinical outcomes in patients with CAD and high LDL-C levels.1,2 But until now it was not known whether aggressive lipid lowering with statins would also benefit CAD patients with very low LDL-C levels."
The current study used the Ibaraki Cardiovascular Assessment Study (ICAS), a registry of 2,238 patients from 12 hospitals in the Ibaraki region of Japan, who between 0 and 1 month underwent percutaneous ...
Dr Benn Christiansen said: "We know that atrial fibrillation increases the risk of ischemic stroke. And in patients with atrial fibrillation or previous ischemic stroke, the risk of stroke increases with the number of risk factors. But until now, little attention has been paid to the association between stroke risk and risk factors in patients without prior stroke or atrial fibrillation. We wanted to explore that association and to quantify if stroke risk was of comparable size in patients with numerous risk factors."
The study included 4,198,119 people aged 18 to 90 ...
Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.1 Prevalence is estimated to double in the next 50 years as the population ages.
Patients with atrial fibrillation have a five-fold increased risk of ischaemic stroke even though around 30% have no symptoms. As blood is less adequately shifted from the heart during atrial fibrillation, blood clots can form and cause large ischaemic strokes. Strokes that occur in association with ...
In contrast, a CHA2DS2-VASc score of 0 identifies a subgroup of patients with very low stroke risk unlikely to benefit from anticoagulation treatment.
Professor Nabauer said: "AF is the most frequent cardiac arrhythmia requiring hospitalisation and has a 1-2% prevalence in the general population. AF is associated with a significant risk of stroke with frequently disabling consequences. While oral anticoagulation is very effective in preventing ischaemic strokes in AF, it increases bleeding risk. Identification of patients with low risk of stroke not requiring oral anticoagulation ...
Cataracts are the leading cause of visual impairment worldwide affecting more than 20 million people. Statins are among the most commonly prescribed medications. In the USA they are prescribed to 1 in 3 people over 45 years of age at a cost of $35 billion annually.
Professor Kostis said: "There is persistent concern among physicians and other health care providers about the possible cataractogenicity of statins.1 We therefore investigated the relationship of statins and cataracts in a meta-analysis of 14 studies selected after detailed review of the medical literature. ...
